SIETES :: 92261 citas

Resultados de la búsqueda por NEUROLOGÍA REFINAR BÚSQUEDA

1.

Joseph A. Panel recommends FDA approval of epilepsy drug derived from marijuana. DIA Daily 2018:1. [Ref.ID 102518]

2.

Anónimo. Cannabinoid-based drug improved symptoms in adults with Tourette syndrome in phase 2 trial. DIA Daily 2018;10 de abril:3. [Ref.ID 102508]

3.

Varadkar S. Cannabidiol for drop seizures in Lennox-Gastaut syndrome. Lancet 2018;391:1006-7. [Ref.ID 102474]

4.

Anónimo. MS stem cell treatment stabilises disease and reduces disability, trial shows. Sheffield Teaching Hospitals News Release 2018:1. [Ref.ID 102471]

5.

Loftus P. Biogen and Abbvie take Multiple sclerosis drug off market. Wall St J 2018:1. [Ref.ID 102466]

6.

Thiele EA, French ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, on behalf of the GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:24 de enero. [Ref.ID 102450]

7.

Whitlock J. Cannabis-derived drug granted priority review. San Diego Business Journal 2018:2 de enero. [Ref.ID 102441]

8.

Uyhazi KE, Miano T, Pan W, VanderBeek BL. Association of novel oral antithrombotics with the risk of intraocular bleeding. Jama Ophthalmol 2017:14 de diciembre. [Ref.ID 102190]

9.

Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ 2017;359:j5024. [Ref.ID 102147]

10.

Wilke RA, Freeman JW. Potential health implications related to fracking. JAMA 2017;318:1645-6. [Ref.ID 102135]

11.

Anónimo. Fingolimod (Gilenya): nuevas contraindicaciones de uso en pacientes con patología cardiaca subyacente y recomendaciones de revisiones dermatológicas. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:6 de noviembre. [Ref.ID 102124]

12.

Poewe W, Seppi K. Insulin signalling: new target for Parkinson's treatments?. Lancet 2017;390:1628-30. [Ref.ID 102093]

13.

Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Li Y, Avilés-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017;390:1664-16875. [Ref.ID 102092]

14.

Anónimo. FDA rules Novo Nordisk’s diabetes drug reduces risk of heart attack, stroke, cardiovascular death. DIA Daily 2017:2. [Ref.ID 102035]

15.

de Koning Svendsen T, Hansen PN, García Rodríguez LA, Andersen L, Hallas J, Sindrup SH, Gaist D. Statins and polyneuropathy revisited: case-control study in Denmark, 1999–2013. Br J Clin Pharmacol 2017;83:2087-95. [Ref.ID 102032]

16.

Mazlan-Kepli W, Macisaac RL, Walters M, Bath PMW, Dawson J, on behalf of the VISTA Collaborators. Interruption to antiplatelet therapy early after acute ischaemic stroke: a nested case–control study. Br J Clin Pharmacol 2017;83:2045-55. [Ref.ID 102030]

17.

Anónimo. Brivaracétam et épilepsie partielle. Prescrire 2017;37:412-3. [Ref.ID 101999]

18.

Jhang KM, Huang J-Y, Nfor ON, Tung Y-C, Ku W-Y, Lee C-T, Liaw Y-P. Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine. Eur J Clin Pharmacol 2017;73:911-6. [Ref.ID 101996]

19.

Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S, Benedetto U. Tolerability of new antiepileptic drugs: a network meta-analysis. Eur J Clin Pharmacol 2017;73:811-7. [Ref.ID 101994]

20.

Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic pot: not your grandfathers marijuana. Trends Pharmacol Sci 2017;38:257-76. [Ref.ID 101989]